ADCT — ADC Therapeutics SA

Is ADCT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

ADC Therapeutics SA (ADCT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.03. The rating moved from Strong Oversold to Oversold on August 18, 2026.

See all oversold Healthcare stocks →

AI analysis

ADC Therapeutics is a small-cap oncology company built on an ADC platform with potential upside from pipeline advancement and biologics-manufacturing tailwinds. Near-term prospects hinge on demonstrating consistent commercial performance, extending clinical proof-of-concept, and securing non-dilutive funding or partnership support. Sector-level dynamics (CDMO demand and payer data-driven cost management) create mixed pressures: outsourcing demand is supportive while reimbursement scrutiny remains a headwind. Given limited public financial visibility and elevated execution risk, the equity is likely to remain volatile and sensitive to clinical updates, financing news, and commercial metrics.

Key factors

  • Commercial-stage antibody-drug conjugate (ADC) platform with at least one prior approved oncology product and a pipeline of ADC candidates that create potential revenue and milestone upside
  • Sector tailwinds for biologics and CDMO/CRO services which can support manufacturing access and outsourcing options for ADC supply
  • Market environment showing mild risk-on tone and stable policy signals, which can modestly improve small-cap biotech sentiment in the near term
  • Ongoing need to demonstrate clear commercial uptake and durable clinical benefit to expand market penetration and negotiate favorable payer terms
  • Limited liquidity and small market cap profile that amplify volatility and make capital-raising dynamics (dilution) a key determinant of near-term equity performance

Risks

  • Tight cash runway and high burn rate that may force dilutive financing or unfavorable partnerships
  • Clinical or regulatory setbacks for pipeline assets that would materially reduce long-term upside
  • Weak commercial execution or slower-than-expected adoption for existing product(s), limiting revenue growth
  • Payer/pricing pressure and strategic rationalization in the healthcare sector that could compress margins and reimbursement levels
  • Manufacturing, supply-chain or CDMO capacity constraints that can delay deliveries and revenue recognition
  • Low trading liquidity and investor attention, increasing susceptibility to sharp price swings on news or financing actions

See today's live rating, score and targets

Members see the live hourly rating for ADCT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.